Paper38108398
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.
Elkrief A and 28 others. Cancer Immunol Res, 2024. Cited by 39 papers, by iCite.
Cite this record
ConductScience Library. Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation. Papers, record 38108398. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38108398
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gastrointestinal Microbiome | Major topic |
| Colitis | Major topic |
| Biological Products | Major topic |
| Humans | |
| Fecal Microbiota Transplantation | |
| Prospective Studies | |
| Dysbiosis | |
| Treatment Outcome |
Source PubMed
Grants9
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 CA023766 | NCI NIH HHS | United States | P01CA023766 | PubMed and NIH | NIH RePORTER |
| R01 CA228308 | NCI NIH HHS | United States | R01CA228308 | PubMed and NIH | NIH RePORTER |
| R01 HL147584 | NHLBI NIH HHS | United States | R01HL147584 | PubMed and NIH | NIH RePORTER |
| P50 CA254838 | NCI NIH HHS | United States | P50CA254838 | PubMed and NIH | NIH RePORTER |
| R01 CA228358 | NCI NIH HHS | United States | R01CA228358 | PubMed and NIH | NIH RePORTER |
| K08 HL143189 | NHLBI NIH HHS | United States | K08HL143189 | PubMed and NIH | NIH RePORTER |
| R01 HL123340 | NHLBI NIH HHS | United States | R01HL123340 | PubMed and NIH | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| P01 AG052359 | NIA NIH HHS | United States | P01AG052359 | PubMed and NIH | NIH RePORTER |
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31488205 | Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31488205 | PubMed |
| 2 | 35082367 | Immune-checkpoint inhibitors: long-term implications of toxicity. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/35082367 | PubMed |
| 3 | 26282644 | Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26282644 | PubMed |
| 4 | 28915085 | Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28915085 | PubMed |
| 5 | 29442540 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29442540 | PubMed |
| 6 | 29255284 | Enterotypes in the landscape of gut microbial community composition. | Nat Microbiol | 2018 | https://conductscience.org/library/papers/29255284 | PubMed |
| 7 | 29975414 | High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. | Cancer | 2018 | https://conductscience.org/library/papers/29975414 | PubMed |
| 8 | 30420754 | Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. | Nat Med | 2018 | https://conductscience.org/library/papers/30420754 | PubMed |
| 9 | 29097493 | Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. | Science | 2018 | https://conductscience.org/library/papers/29097493 | PubMed |
| 10 | 31328416 | Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. | Thorac Cancer | 2019 | https://conductscience.org/library/papers/31328416 | PubMed |
| 11 | 32603654 | Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. | Cell | 2020 | https://conductscience.org/library/papers/32603654 | PubMed |
| 12 | 27126039 | Population-level analysis of gut microbiome variation. | Science | 2016 | https://conductscience.org/library/papers/27126039 | PubMed |
| 13 | 32847937 | The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. | Cancer Immunol Res | 2020 | https://conductscience.org/library/papers/32847937 | PubMed |
| 14 | 33675691 | Understanding and treating the inflammatory adverse events of cancer immunotherapy. | Cell | 2021 | https://conductscience.org/library/papers/33675691 | PubMed |
| 15 | 33246931 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. | ESMO Open | 2020 | https://conductscience.org/library/papers/33246931 | PubMed |
| 16 | 34239137 | Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. | Nat Med | 2021 | https://conductscience.org/library/papers/34239137 | PubMed |
| 17 | 29617710 | Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. | Ann Oncol | 2018 | https://conductscience.org/library/papers/29617710 | PubMed |
| 18 | 35194180 | Regulation of tissue-resident memory T cells by the Microbiota. | Mucosal Immunol | 2022 | https://conductscience.org/library/papers/35194180 | PubMed |
| 19 | 33171025 | The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. | Cancer Res Treat | 2021 | https://conductscience.org/library/papers/33171025 | PubMed |
| 20 | 32294209 | Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. | J Natl Cancer Inst | 2021 | https://conductscience.org/library/papers/32294209 | PubMed |
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42913630 | Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade. | Cell | 2026 | https://conductscience.org/library/papers/42913630 | PubMed |
| 42903966 | Interactions between microbiota and innate immunity in tumor microenvironment: Novel insights into cancer progression and immunotherapy. | Hlife | 2025 | https://conductscience.org/library/papers/42903966 | PubMed |
| 42735684 | First-line fecal microbiota transplantation for the management of immune checkpoint inhibitor-mediated diarrhea and colitis. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42735684 | PubMed |
| 42721039 | B cell-guided inflammatory cascade perpetuates ICI-mediated colitis. | Cell Rep | 2026 | https://conductscience.org/library/papers/42721039 | PubMed |
| 42602359 | Application and prospects of fecal microbiota transplantation in cancer therapy. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42602359 | PubMed |
| 42564206 | Integrated cellular, proteomic and metabolomic profiling of immune-related adverse events in non-small cell lung cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42564206 | PubMed |
| 42493518 | Microbial engraftment and immune regulation during fecal microbiota transplantation and immune checkpoint inhibitor therapy. | Nat Commun | 2026 | https://conductscience.org/library/papers/42493518 | PubMed |
| 42233032 | Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025). | Front Immunol | 2026 | https://conductscience.org/library/papers/42233032 | PubMed |
| 42204645 | Decoding the microbiome-immune crosstalk in cancer: from mechanisms to therapeutic translation. | Biomark Res | 2026 | https://conductscience.org/library/papers/42204645 | PubMed |
| 42083059 | Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer. | Microbiome | 2026 | https://conductscience.org/library/papers/42083059 | PubMed |
| 41992000 | Microbiota and immune-related adverse events in cancer immunotherapy. | Nat Rev Cancer | 2026 | https://conductscience.org/library/papers/41992000 | PubMed |
| 41898402 | Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41898402 | PubMed |
| 41644742 | Toward Microbiome-Informed Melanoma Care: The Gut Microbiota in Melanoma Evolution, Immunotherapy Response and Immune-Related Toxicity. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/41644742 | PubMed |
| 41606121 | Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. | Nat Med | 2026 | https://conductscience.org/library/papers/41606121 | PubMed |
| 41606120 | Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial. | Nat Med | 2026 | https://conductscience.org/library/papers/41606120 | PubMed |
| 41545303 | Steroid-sparing strategies for managing immune-related adverse events. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41545303 | PubMed |
| 41535719 | Gut dysbiosis in oncology: a risk factor for immunoresistance. | Cell Res | 2026 | https://conductscience.org/library/papers/41535719 | PubMed |
| 41374078 | Inflammatory Bowel Disease, Gastrointestinal Graft-Versus-Host Disease and Immune Checkpoint Inhibitors Induced Colitis: Similar Diseases to Treat with Fecal Microbiota Transplantation. | Nutrients | 2025 | https://conductscience.org/library/papers/41374078 | PubMed |
| 41349548 | Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting. | Annu Rev Immunol | 2026 | https://conductscience.org/library/papers/41349548 | PubMed |
| 41304963 | Fecal Microbiota Transplantation in Refractory Immune-Mediated Colitis: Case Series and Review of the Literature. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41304963 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38108398
GET https://conductscience.org/api/papers/v1/38108398/authors?page=2